Pharmacokinetics of linezolid treatment using intravenous and oral administrations in extremely premature infants (Q33420904)

9

object named as

Christèle Gras-Le Guen

0 references

Elise Launay

object named as

Elise Launay

2

0 references

author name string

Mélanie Sicard

1

1 reference

26 July 2017

Jocelyne Caillon

3

1 reference

26 July 2017

Cédric Jacqueline

4

1 reference

26 July 2017

Arnaud Legrand

5

1 reference

26 July 2017

Guillaume Deslandes

6

1 reference

26 July 2017

Dominique Navas

7

1 reference

26 July 2017

Christèle Gras-Le Guen

European Journal of Clinical Pharmacology

9

1 reference

26 July 2017

6 March 2015

1 reference

26 July 2017

1 reference

26 July 2017

71

1 reference

26 July 2017

611-615

1 reference

26 July 2017

5

1 reference

26 July 2017

https://scigraph.springernature.com/pub.10.1007/s00228-015-1813-3

0 references

cites work

Early and late onset sepsis in late preterm infants

1 reference

https://api.crossref.org/works/10.1007%2FS00228-015-1813-3

Vancomycin elimination in human infants with intrauterine growth retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-015-1813-3

Neurologic outcomes at school age in very preterm infants born with severe or mild growth restriction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-015-1813-3

Activities of respiratory chain complexes and pyruvate dehydrogenase in isolated muscle mitochondria in premature neonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-015-1813-3

In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-015-1813-3

Linezolid pharmacokinetics in pediatric patients: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-015-1813-3

Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-015-1813-3

Impact of ontogeny on linezolid disposition in neonates and infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-015-1813-3

Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-015-1813-3

Hematologic effects of linezolid in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-015-1813-3

Safety and tolerability of linezolid in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-015-1813-3

Linezolid and lactic acidosis: a role for lactate monitoring with long-term linezolid use in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-015-1813-3

Long-term trends in the epidemiology of neonatal sepsis and antibiotic susceptibility of causative agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-015-1813-3

Linezolid: effectiveness and safety for approved and off-label indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-015-1813-3

Diagnosis and treatment of early bacterial infection in newborns

21 January 2018

1 reference

12 December 2020

Safety and tolerability of linezolid

1 reference

12 December 2020

Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens

1 reference

12 December 2020

The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria

1 reference

12 December 2020

LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers)

1 reference

12 December 2020

Prevalence of nosocomial infections in neonatal intensive care unit patients: Results from the first national point-prevalence survey

1 reference

12 December 2020